PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Saint Ladislaus Campus, H-1097 Albert Florian ut 5‑7., Budapest, Hungary. szabo.balint.gergely@gmail.com.\', \'Doctoral School of Clinical Medicine, Semmelweis University, H-1085 Ulloi ut 26, Budapest, Hungary. szabo.balint.gergely@gmail.com.\', \'South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Saint Ladislaus Campus, H-1097 Albert Florian ut 5‑7., Budapest, Hungary.\', \'Faculty of Medicine, Semmelweis University, H-1085 Ulloi ut 26, Budapest, Hungary.\', \'Doctoral School of Clinical Medicine, Semmelweis University, H-1085 Ulloi ut 26, Budapest, Hungary.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s11357-021-00452-9
?:hasPublicationType
?:journal
  • GeroScience
is ?:pmid of
?:pmid
?:pmid
  • 34476717
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.168
?:rankingScore_hIndex
  • 45
is ?:relation_isRelatedTo_publication of
?:title
  • Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all